Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ultragenyx Pharmaceutical (RARE) Return on Capital Employed: 2017-2025

Historic Return on Capital Employed for Ultragenyx Pharmaceutical (RARE) over the last 9 years, with Sep 2025 value amounting to -0.60%.

  • Ultragenyx Pharmaceutical's Return on Capital Employed fell 18.00% to -0.60% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.60%, marking a year-over-year decrease of 18.00%. This contributed to the annual value of -0.46% for FY2024, which is negligibly% changed negligibly from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's Return on Capital Employed is -0.60%, which was down 20.45% from -0.50% recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Return on Capital Employed high stood at -0.20% for Q1 2021, and its period low was -0.61% during Q2 2023.
  • In the last 3 years, Ultragenyx Pharmaceutical's Return on Capital Employed had a median value of -0.50% in 2024 and averaged -0.51%.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's Return on Capital Employed increased by 25bps in 2021, and later declined by 21bps in 2022.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Return on Capital Employed stood at -0.29% in 2021, then fell by 20bps to -0.49% in 2022, then dropped by 3bps to -0.53% in 2023, then rose by 7bps to -0.46% in 2024, then decreased by 18bps to -0.60% in 2025.
  • Its Return on Capital Employed was -0.60% in Q3 2025, compared to -0.50% in Q2 2025 and -0.46% in Q1 2025.